The market for recovery compounds has a bedtime shelf. Delta sleep-inducing peptide is sold on its name, growth-hormone secretagogues are sold on the fact that most growth hormone is released during deep sleep, and both are pitched at the lifter who trains hard and sleeps badly.
The premise is sound. The comparison nobody runs is between those compounds and the thing they are supposed to substitute for — and it does not go the way the shelf implies.
This is research journalism. It reports what the sources state, including the amounts used in trials and on labels where those are on the record, each figure carrying its source and date — and it never tells anyone what to take.
The sleep peptide with a name and no file
Delta sleep-inducing peptide was isolated in the 1970s from the blood of rabbits whose brains were showing delta-wave activity, and it was named for that observation. Half a century later the record is thin in a specific way — not empty, but frozen.
PubMed holds 518 records mentioning it. Only 11 of them have been published since 2015, and only 7 mention randomisation anywhere. An intervention search of ClinicalTrials.gov returns one registration. For scale, the same search returns 24 registrations for the one approved GHRH analogue and 27 for the one that lost its approval — two compounds this site covers precisely because their records are unusually complete.
A literature that stops is different from a literature that never started. Something was studied, interest faded, and nothing since has revived it. That pattern is worth naming because vendor copy tends to present the 1970s work as foundational rather than as the end of the line.
What five bad nights do to muscle protein
The strongest human data on this page is not about a compound at all.
Twenty-four healthy young men were assigned to five nights of eight hours in bed, five nights of four hours, or five nights of four hours plus three high-intensity interval sessions (PMID 32078168, Journal of Physiology, 2020). Deuterium oxide tracing and muscle biopsies before and after gave the rate of myofibrillar protein synthesis — the assembly rate of contractile muscle protein, which is the variable a recovery product would need to move.
| Five-night condition | Myofibrillar protein synthesis (% per day) |
|---|---|
| Eight hours in bed | 1.53 |
| Four hours in bed | 1.24 |
| Four hours in bed, with interval training | 1.61 |
Two things sit in that table. Sleep restriction lowered the rate by about a fifth. And exercise, performed while still sleep-restricted, held it at the normal-sleep level.
The second result deserves care. It is one mechanistic endpoint, in 24 young men, over five nights, with no measurement of performance, mood or injury risk. It is not evidence that training cancels sleep debt. It is evidence that the protein-synthesis pathway specifically was defended by exercise in that window — which is a narrower and more interesting claim.
The fortnight that shows where the weight comes from
The second controlled study asked a blunter question: during a diet, does sleep change what the body gives up?
Ten overweight adults completed two 14-day periods of identical moderate calorie restriction in a randomised crossover, one with 8.5 hours of sleep opportunity and one with 5.5 (PMID 20921542, Annals of Internal Medicine, 2010).
| Outcome over 14 days | 8.5 h sleep opportunity | 5.5 h sleep opportunity |
|---|---|---|
| Fat lost | 1.4 kg | 0.6 kg |
| Fat-free mass lost | 1.5 kg | 2.4 kg |
Total weight loss was similar. Its composition was not: short sleep cut the proportion lost as fat by 55% and increased fat-free mass loss by 60%, alongside greater hunger and a shift in substrate use away from fat oxidation.
The arithmetic worth carrying away from this page is what that 0.9 kg of spared lean tissue is worth in context. Across the growth-hormone axis — the mechanism every sleep-marketed peptide invokes — the measured lean-mass gains cluster tightly: about 1.1 kg over twelve months for MK-677, about 1.4 kg for capromorelin, and 1.42 kg in pooled trials of tesamorelin. Two weeks of adequate versus short sleep, during a diet, moved lean tissue by 0.9 kg. The free variable operates on the same scale as the pharmacology, in a twenty-sixth of the time.
That comparison is imperfect and stated as such: sparing tissue during a deficit is not the same event as adding tissue, the sleep trials are tiny, and the compound trials ran in older or clinical populations. What it does establish is that a lifter dismissing sleep as soft while buying a compound for the same pathway has the magnitudes upside down.
The one study run on athletes
Eleven men on Stanford's varsity basketball team kept their habitual schedule for two to four weeks, then aimed for at least ten hours in bed nightly for five to seven weeks (PMID 21731144, Sleep, 2011). Objective sleep rose by 111 minutes a night.
Their timed sprint fell from 16.2 to 15.5 seconds. Free-throw accuracy rose 9%, three-point accuracy 9.2%, and reaction time, sleepiness and mood scores all improved — every comparison at p < 0.001.
It is also the weakest design on this page: no control group, no blinding, and a season's worth of coaching and practice running underneath the intervention. Basketball players shooting better after several weeks of practice is not a surprising outcome. The study is worth citing because it is the only sleep-extension experiment in this literature run on trained athletes with sport-specific measures, and honest reporting means naming both facts.
Where the compounds actually sit
For a tested athlete the comparison is not close, and it is not about efficacy. Sleep is unregulated by any anti-doping code. Growth hormone, its fragments and its releasing factors are prohibited at all times, which covers the secretagogues sold on the bedtime shelf — the per-compound detail is on our drug-testing page.
The rest of the recovery question — tendons, joints, injury timelines — is handled separately in what the evidence shows on joints and tendons and in peptides for recovery. What belongs here is the narrower finding: on the specific outcome of protecting and building muscle tissue, the sleep interventions have randomised human trials with muscle endpoints, and the sleep compounds have a registry entry and a literature that stopped when their discoverers retired.